Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cancer Research UK
OBJECTIVES:
* Determine the safety of carboplatin and thalidomide in patients with stage IC-IV ovarian cancer.
* Determine the antiangiogenic effect of thalidomide in this patient population.
* Compare the efficacy of carboplatin with or without thalidomide in this patient population.
OUTLINE: This is a randomized study. Patients are randomized to one of two treatment arms.
* Arm I: Patients receive carboplatin IV over 1 hour. Treatment continues every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
* Arm II: Patients receive carboplatin as in arm I. Patients receive thalidomide orally once daily. Thalidomide treatment continues for up to 24 weeks commencing on the first day of carboplatin therapy and ceasing 4 weeks after the last course of carboplatin.
PROJECTED ACCRUAL: Approximately 30 patients will be accrued for this study.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
DISEASE CHARACTERISTICS:
Histologically confirmed stage IC-IV ovarian epithelial cancer
Post-menopausal OR
Prior bilateral salpingo-oophorectomy and/or total abdominal hysterectomy
PATIENT CHARACTERISTICS:
Age:
Over 18
Performance status:
WHO 0-2
Life expectancy:
Not specified
Hematopoietic:
Not specified
Hepatic:
Not specified
Renal:
Not specified
Other:
No other concurrent invasive malignancies
Not pregnant
No diabetes mellitus
No chronic neurological disease causing peripheral neuropathy
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Not specified
Chemotherapy:
No other concurrent cytotoxic agents
Endocrine therapy:
Not specified
Radiotherapy:
Concurrent local radiotherapy for treatment of secondary disease sites allowed
Surgery:
See Disease Characteristics
Clareo Health | Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial Cancer
